BioArctic (BIOA B) Stock Overview
Develops biological drugs for patients with central nervous system disorders in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BIOA B Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 300.00 |
| 52 Week High | SEK 364.40 |
| 52 Week Low | SEK 154.40 |
| Beta | -0.90 |
| 1 Month Change | -9.31% |
| 3 Month Change | -2.47% |
| 1 Year Change | 39.15% |
| 3 Year Change | 14.42% |
| 5 Year Change | 214.80% |
| Change since IPO | 934.48% |
Recent News & Updates
Recent updates
BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 16
Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%
Aug 14
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.BioArctic's (STO:BIOA B) Solid Profits Have Weak Fundamentals
May 29Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders Concerns
May 16Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Feb 19Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Feb 18Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)
Jan 31Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Nov 27BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 01Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
Aug 15Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Shareholder Returns
| BIOA B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.0% | -3.3% | -3.8% |
| 1Y | 39.1% | 7.2% | 3.8% |
Return vs Industry: BIOA B exceeded the Swedish Biotechs industry which returned 5% over the past year.
Return vs Market: BIOA B exceeded the Swedish Market which returned 4.6% over the past year.
Price Volatility
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BIOA B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BIOA B's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 131 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases.
BioArctic AB (publ) Fundamentals Summary
| BIOA B fundamental statistics | |
|---|---|
| Market cap | SEK 26.62b |
| Earnings (TTM) | SEK 1.02b |
| Revenue (TTM) | SEK 2.00b |
Is BIOA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA B income statement (TTM) | |
|---|---|
| Revenue | SEK 2.00b |
| Cost of Revenue | SEK 59.22m |
| Gross Profit | SEK 1.94b |
| Other Expenses | SEK 917.57m |
| Earnings | SEK 1.02b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 09, 2026
| Earnings per share (EPS) | 11.52 |
| Gross Margin | 97.04% |
| Net Profit Margin | 51.14% |
| Debt/Equity Ratio | 0% |
How did BIOA B perform over the long term?
See historical performance and comparisonDividends
Does BIOA B pay a reliable dividends?
See BIOA B dividend history and benchmarks| BioArctic dividend dates | |
|---|---|
| Ex Dividend Date | May 29 2026 |
| Dividend Pay Date | Jun 04 2026 |
| Days until Ex dividend | 83 days |
| Days until Dividend pay date | 89 days |
Does BIOA B pay a reliable dividends?
See BIOA B dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 17:04 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioArctic AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |
| Viktor Sundberg | Nordea Markets |